Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons

Acta Neuropathologica

Volumn 121, Issue 4, 2011, Pages 475-485

  Garrido, Manuel ^a   Tereshchenko, Yuliya ^a   Zhevtsova, Zinayida ^a   Taschenberger, Grit ^a   Bähr, Mathias ^a   Kügler, Sebastian ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Synuclein; Glutathione; Parkinson's disease; RNAi

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; PARVOVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; DOWN REGULATION; FEMALE; GLUTATHIONE METABOLISM; MOTOR DYSFUNCTION; NERVE CELL DEGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; RNA INTERFERENCE; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; CATALYTIC DOMAIN; CELL SURVIVAL; CYSTEINE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGONISTS; FEMALE; GENE EXPRESSION REGULATION; GLIOSIS; GLUTATHIONE; GLUTATHIONE REDUCTASE; GREEN FLUORESCENT PROTEINS; MOVEMENT; NERVE DEGENERATION; RATS; RATS, WISTAR; RNA, SMALL INTERFERING; SENSATION DISORDERS; STEREOTYPED BEHAVIOR; SUBSTANTIA NIGRA; TIME FACTORS; TRANSDUCTION, GENETIC; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 79954575965     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-010-0791-x     Document Type: Article

References (38)

1. TV Achenbach B Brunner K Heermeier 2003 Oligonucleotide-based knockdown technologies: antisense versus RNA interference Chembiochem 4 928 935 14523910 10.1002/cbic.200300708 1:CAS:528:DC%2BD3sXotlSrtrY%3D (Pubitemid 37267581)
2. S Chandra G Gallardo R Fernandez-Chacon OM Schlüter TC Südhof 2005 Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration Cell 123 383 396 16269331 10.1016/j.cell.2005.09.028 1:CAS:528: DC%2BD2MXht1altLnN (Pubitemid 41546670)
3. SJ Chinta JK Andersen 2006 Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease Free Radic Biol Med 41 1442 1448 17023271 10.1016/j.freeradbiomed.2006.08.002 1:CAS:528:DC%2BD28XhtVCrtLbE (Pubitemid 44466728)
4. SJ Chinta MJ Kumar M Hsu, et al. 2007 Inducible alterations of glutathione levels in adult dopaminergic midbrain neurons result in nigrostriatal degeneration J Neurosci 27 13997 14006 18094238 10.1523/JNEUROSCI.3885-07.2007 1:CAS:528:DC%2BD1cXisVGhtg%3D%3D (Pubitemid 351377875)
5. CY Chung JB Koprich H Siddiqi O Isacson 2009 Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy J Neurosci 29 3365 3373 19295143 10.1523/JNEUROSCI.5427- 08.2009 1:CAS:528:DC%2BD1MXjs1Wmtb0%3D
6. I Dalle-Donne R Rossi G Colombo D Giustarini A Milzani 2009 Protein S-glutathionylation: a regulatory device from bacteria to humans Trends Biochem Sci 34 85 96 19135374 10.1016/j.tibs.2008.11.002 1:CAS:528:DC%2BD1MXitVOkurg%3D
7. TP Dalton MZ Dieter Y Yang HG Shertzer DW Nebert 2000 Knockout of the mouse glutamate cysteine ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous Biochem Biophys Res Commun 279 324 329 11118286 10.1006/bbrc.2000.3930 1:CAS:528:DC%2BD3cXovVCntr4%3D (Pubitemid 32016716)
8. JI Diaz-Hernandez A Almeida M Delgado-Esteban E Fernandez JP Bolanos 2005 Knockdown of glutamate-cysteine ligase by small hairpin RNA reveals that both catalytic and modulatory subunits are essential for the survival of primary neurons J Biol Chem 280 38992 39001 16183645 10.1074/jbc.M507065200 1:CAS:528:DC%2BD2MXht1emsrrP (Pubitemid 41713849)
9. R Dringen 2000 Metabolism and functions of glutathione in brain Prog Neurobiol 62 649 671 10880854 10.1016/S0301-0082(99)00060-X 1:CAS:528: DC%2BD3cXksFentLg%3D (Pubitemid 30407139)
10. R Dringen B Hamprecht 1996 Glutathione content as an indicator for the presence of metabolic pathways of amino acids in astroglial cultures J Neurochem 67 1375 1382 8858918 10.1046/j.1471-4159.1996.67041375.x 1:CAS:528: DyaK28XmtVWitr0%3D (Pubitemid 26314191)
11. L Greenbaum C Rothmann R Lavie Z Malik 2000 Green fluorescent protein photobleaching: a model for protein damage by endogenous and exogenous singlet oxygen Biol Chem 381 1251 1258 11209760 10.1515/BC.2000.153 1:CAS:528: DC%2BD3MXhsFegsbo%3D (Pubitemid 32094437)
12. J Hardy P Lewis T Revesz A Lees C Paisan-Ruiz 2009 The genetics of Parkinson's syndromes: a critical review Curr Opin Genet Dev 19 254 265 19419854 10.1016/j.gde.2009.03.008 1:CAS:528:DC%2BD1MXnt1Gmu74%3D
13. A Henschel F Buchholz B Habermann 2004 DEQOR: a web-based tool for the design and quality control of siRNAs Nucleic Acids Res 32 W113 W120 15215362 10.1093/nar/gkh408 1:CAS:528:DC%2BD2cXlvFKnsLY%3D (Pubitemid 38997311)
14. EC Hirsch S Hunot 2009 Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8 382 397 19296921 10.1016/S1474-4422(09) 70062-6 1:CAS:528:DC%2BD1MXks1Sis70%3D
15. R Janaky K Ogita BA Pasqualotto, et al. 1999 Glutathione and signal transduction in the mammalian CNS J Neurochem 73 889 902 10461878 10.1046/j.1471-4159.1999.0730889.x 1:CAS:528:DyaK1MXlsVOisbo%3D (Pubitemid 29395445)
16. KA Jellinger 2008 A critical reappraisal of current staging of Lewy-related pathology in human brain Acta Neuropathol 116 1 16 18592254 10.1007/s00401-008-0406-y 1:CAS:528:DC%2BD1cXosVOjtbw%3D
17. P Jenner 2008 Functional models of Parkinson's disease: a valuable tool in the development of novel therapies Ann Neurol 64 Suppl 2 S16 S29 19127585 1:CAS:528:DC%2BD1MXhsFKjsrc%3D
18. P Jenner DT Dexter J Sian AH Schapira CD Marsden 1992 Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group Ann Neurol 32 Suppl S82 S87 1510385 10.1002/ana.410320714 1:CAS:528: DyaK3sXnvVSntQ%3D%3D
19. S Kowsky C Poppelmeyer ER Kramer, et al. 2007 RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals Proc Natl Acad Sci USA 104 20049 20054 18056810 10.1073/pnas. 0706177104 1:CAS:528:DC%2BD1cXhs1Krsw%3D%3D
20. S Kügler P Lingor U Schöll S Zolotukhin M Bähr 2003 Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units Virology 311 89 95 12832206 10.1016/S0042-6822(03)00162-4 (Pubitemid 36794213)
21. E Kuusisto L Parkkinen I Alafuzoff 2003 Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62 J Neuropathol Exp Neurol 62 1241 1253 14692700 1:CAS:528:DC%2BD2cXht1Onsw%3D%3D (Pubitemid 37494193)
22. OA Levy C Malagelada LA Greene 2009 Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps Apoptosis 14 478 500 19165601 10.1007/s10495-008-0309-3
23. I Malik M Garrido M Bähr S Kügler U Michel 2006 Comparison of test systems for RNA interference Biochem Biophys Res Commun 341 245 253 16423323 10.1016/j.bbrc.2005.12.173 1:CAS:528:DC%2BD28XoslyhtA%3D%3D (Pubitemid 43117411)
24. JM Malik Z Shevtsova M Bähr S Kügler 2005 Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer Mol Ther 11 373 381 15727933 10.1016/j.ymthe.2004.11.014 1:CAS:528:DC%2BD2MXhsVOjurs%3D (Pubitemid 40277313)
25. HL Martin P Teismann 2009 Glutathione - a review on its role and significance in Parkinson's disease FASEB J 23 3263 3272 19542204 10.1096/fj.08-125443 1:CAS:528:DC%2BD1MXht1GjtLnO
26. K Nakamura DA Wright T Wiatr, et al. 2000 Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin J Neurochem 74 2305 2314 10820190 10.1046/j.1471-4159.2000.0742305.x 1:CAS:528:DC%2BD3cXjsVKku7Y%3D (Pubitemid 30314205)
27. RK Pearce A Owen S Daniel P Jenner CD Marsden 1997 Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease J Neural Transm 104 661 677 9444566 10.1007/BF01291884 1:STN:280: DyaK1c7gs12ksw%3D%3D (Pubitemid 27474680)
28. TL Perry DV Godin S Hansen 1982 Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33 305 310 7162692 10.1016/0304-3940(82)90390-1 1:STN:280:DyaL3s7kt1aktA%3D%3D (Pubitemid 13119539)
29. TL Perry VW Yong 1986 Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients Neurosci Lett 67 269 274 3737015 10.1016/0304-3940(86)90320-4 1:STN:280:DyaL283osFKluw%3D%3D (Pubitemid 16038336)
30. P Riederer E Sofic WD Rausch, et al. 1989 Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains J Neurochem 52 515 520 2911028 10.1111/j.1471-4159.1989.tb09150.x 1:CAS:528:DyaL1MXhtFals78%3D (Pubitemid 19037617)
31. RK Schwarting JP Huston 1996 The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments Prog Neurobiol 50 275 331 8971983 10.1016/S0301-0082(96)00040-8 1:CAS:528:DyaK2sXks12hsQ%3D%3D (Pubitemid 26412599)
32. Z Shevtsova I Malik M Garrido U Schöll M Bähr S Kügler 2006 Potentiation of in vivo neuroprotection by BclX(L) and GDNF co-expression depends on post-lesion time in deafferentiated CNS neurons Gene Ther 13 1569 1578 16838029 10.1038/sj.gt.3302822 1:CAS:528:DC%2BD28XhtFKlt77K (Pubitemid 44688457)
33. J Sian DT Dexter AJ Lees, et al. 1994 Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia Ann Neurol 36 348 355 8080242 10.1002/ana.410360305 1:STN:280: DyaK2czmtFCltg%3D%3D (Pubitemid 24280055)
34. Thomas B, Beal MF (2007) Parkinson's disease. Hum Mol Genet 16(Spec No. 2):R183-R194
35. S Toffa GM Kunikowska BY Zeng P Jenner CD Marsden 1997 Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration J Neural Transm 104 67 75 9085194 10.1007/BF01271295 1:CAS:528:DyaK2sXis1eisrc%3D (Pubitemid 27073230)
36. J Wang ES Boja W Tan, et al. 2001 Reversible glutathionylation regulates actin polymerization in A431 cells J Biol Chem 276 47763 47766 11684673 1:CAS:528:DC%2BD38XkvFWh
37. NE Ward JR Stewart CG Ioannides CA O'Brian 2000 Oxidant-induced S-glutathiolation inactivates protein kinase C-alpha (PKC-alpha): a potential mechanism of PKC isozyme regulation Biochemistry 39 10319 10329 10956021 10.1021/bi000781g 1:CAS:528:DC%2BD3cXltVOjsbk%3D (Pubitemid 30663054)
38. GD Zeevalk R Razmpour LP Bernard 2008 Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62 236 249 18400456 10.1016/j.biopha.2008.01.017 1:CAS:528:DC%2BD1cXls1Sisb0%3D (Pubitemid 351626446)